Clinical Trials
43 trialsMITHRIDATE
University of Birmingham
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
C-SMART
Peter MacCallum Cancer Centre, Australia
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin
Eastern Cooperative Oncology Group
Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Fudan University
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
MCLelderly
European Mantle Cell Lymphoma Network
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Alliance for Clinical Trials in Oncology
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
SWOG Cancer Research Network
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
University of Alabama at Birmingham
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
National Cancer Institute (NCI)
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma
National Cancer Institute (NCI)
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
National Cancer Institute (NCI)
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis
Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
National Cancer Institute (NCI)
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma
Hackensack Meridian Health
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Novartis
ARCC
Pfizer
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
National Cancer Institute (NCI)
FOGT1
University of Ulm
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
Università Politecnica delle Marche
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
Centre Leon Berard